UAE: OPEC Ready to Boost Oil Supply

Source: Bloomberg (2/14/11)

"IEA forecasts global consumption will rise to 89.3 Mbbls./day in 2011."

"The market is well supplied," said Energy Minister Mohammed Al Hamli, "Signs are coming—and they are positive—that there will be a gradual increase in demand."

OPEC producers are watching prices because they don't want rising crude costs to destroy demand, he said, adding, "We don't want to see demand adversely affected by high prices."

Oil prices have risen in reaction to global events like the uprising in Egypt that led President Mubarak to step down after 30 years of rule, he said. Brent crude exceeded $100 last month.

There is a "decoupling" between prices for Brent and U.S. benchmark West Texas Intermediate, Al Hamli said. This was because of "technical reasons," including inventories in the US and the actions of traders, he said at an event to commemorate OPEC's 50th anniversary.

Brent crude for April settlement climbed as much as $3.02 to $103.9/barrel and was at $103.7 at 3:23 pm local time on the ICE Futures Europe exchange. WTI for March delivery on the NYMEX was at $86.3/barrel, up $0.72.

OPEC may boost supply as crude demand rises along with a recovery in global economic growth to rates approaching those last seen before the financial crisis, Saudi Arabia's Oil Minister Ali al Naimi said last month.

On January 24, Al Naimi said OPEC's policy "is to meet any increase in oil demand to maintain the supply demand balance."

The UAE is producing 2.2 Mbbls./day, within its OPEC quota, Al Hamli said. He said the UAE's "sustainable" output capacity is 2.8 Mbbls./day.

On February 10, the IEA raised its crude demand-growth forecast for a fifth consecutive month. Global consumption will rise in 2011 1.7%, to 89.3 Mbbls./day, it said. The forecast equates with the low end of the demand increase Al Naimi said OPEC foresees.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.